VolitionRx Limited announced the formation of a subsidiary, Volition Veterinary Diagnostics Development LLC (Volition Veterinary), and the appointment of animal health expert Nathan Dewsbury as its Chief Executive Officer. Mr. Dewsbury has global expertise in the animal health industry having direct involvement in national testing programs, current health diagnostics platforms and commercializing next generation diagnostics. He has a strong background in forming new commercial teams as well as launching and growing successful animal focused startups, all to achieve a global impact on the lives of animals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7236 USD | +0.49% | -8.04% | +0.92% |
05-14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
05-13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.92% | 59.93M | |
-27.70% | 9.87B | |
+27.06% | 2.89B | |
-16.78% | 2.75B | |
-15.31% | 2.13B | |
-21.41% | 1.65B | |
+68.70% | 1.47B | |
+29.75% | 811M | |
-5.02% | 733M | |
-29.39% | 510M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- VolitionRx Limited Forms Texas-Based Veterinary Subsidiary; Appoints Nathan Dewsbury its Chief Executive Officer